Designing Better Molecules, Atom by Atom

Our drug discovery efforts are focused on three areas: heterobifunctionals, covalency and designing best-in-class small molecules.

QUAISAR Platform

A platform to improve the quality of chemical matter in our drug discovery projects


QUAISAR Platform

We use computational physics and artificial intelligence to improve the quality of chemical matter to enable drug discovery.

Read More


Quantum Mechanics

Quantum mechanics is the most accurate way to simulate the behavior of molecules and interactions between molecules.

Read More



We use statistical thermodynamics to compute biologically relevant quantities such as binding affinity, selectivity, allostery, membrane permeability and solubility.

Read More


Molecular Simulations

Molecular Simulation allows us to predict interactions, energies and the conformational behavior of our drug discovery targets.

Read More


Artificial Intelligence and Machine Learning

Artificial intelligence (AI) and machine learning (ML) at Roivant Discovery leverage data and cutting-edge algorithms to solve real-world problems in drug discovery.

Read More


Supercomputing Infrastructure

Our dedicated, built-for-purpose, super-computing cluster provides the computing power necessary to deliver the most accurate results at scale.

Read More

Science Leadership

We are committed to advancing science and improving human health

Matt Maisak, PhD

Chief Operating Officer, Roivant Platforms

Plus Sign

Iván Cornella-Taracido, PhD

Vice President of Translational Chemical Biology

Plus Sign

Huafeng Xu, PhD

Chief Technology Officer

Plus Sign

Eric Valeur, PhD

Vice President, Head of Drug Discovery

Plus Sign

Jason Imbriglio, PhD

Vice President, Discovery Chemistry

Plus Sign

Tudor Oprea, MD, PhD

Vice President, Translational Informatics

Plus Sign

Learn More

A Paradigm Shift in Molecular Medicine

video section decoration

Atomic-Resolution Prediction of TPD Complex Structures by Combining MD with Experimental HDX-MS

About Us

Where we come from and where we’re going

Discover how our model aligns incentives to drive fast, high-quality execution and rigorous capital allocation.

Our Companies

Nimble, entrepreneurial Vants

Explore our diverse family of biopharmaceutical and health technology companies.